A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson's Disease
Latest Information Update: 24 Aug 2023
At a glance
- Drugs Vipadenant (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Biogen
- 25 May 2007 New trial record.